MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8+ T lymphocytes

Vaccine

Volumn 29, Issue 27, 2011, Pages 4476-4484

  Mendes, Érica A ^a   Caetano, Bráulia C ^b   Penido, Marcus L O ^a   Bruna Romero, Oscar ^a   Gazzinelli, Ricardo T ^a,b,c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Recombinant adenovirus 5; Surface antigen 1; T. gondii vaccine

Indexed keywords

ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; MYELOID DIFFERENTIATION FACTOR 88; SURFACE ANTIGEN 1; SURFACE ANTIGEN 2; SURFACE ANTIGEN 3; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HOST; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; TOXOPLASMA GONDII; VACCINATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

EID: 79958108787     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.044     Document Type: Article

References (68)

1. Hartman Z.C., Appledorn D.M., Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008, 132(1-2):1-14.
2. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol;8(1):62-73.
3. Gao G., Wang Q., Dai Z., Calcedo R., Sun X., Li G., et al. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. Hum Gene Ther 2008, 19(9):927-936.
4. Bayer W., Tenbusch M., Lietz R., Johrden L., Schimmer S., Uberla K., et al. Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. J Virol 2010, 84(4):1967-1976.
5. Holst P.J., Orskov C., Thomsen A.R., Christensen J.P. Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol 2010, 184(8):4431-4439.
6. Makedonas G., Hutnick N., Haney D., Amick A.C., Gardner J., Cosma G., et al. Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8T cells. PLoS Pathog 2010, 6(3):e1000798.
7. Lindsay R.W., Darrah P.A., Quinn K.M., Wille-Reece U., Mattei L.M., Iwasaki A., et al. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of tlr and nucleotide-binding oligomerization domain-like receptor signaling. J Immunol 2010, 185(3):1513-1521.
8. Howell M.R., Nang R.N., Gaydos C.A., Gaydos J.C. Prevention of adenoviral acute respiratory disease in Army recruits: cost-effectiveness of a military vaccination policy. Am J Prev Med 1998, 14(3):168-175.
9. Hidajat R., Kuate S., Venzon D., Kalyanaraman V., Kalisz I., Treece J., et al. Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains. Vaccine 2010, 28(23):3963-3971.
10. Thacker E.E., Nakayama M., Smith B.F., Bird R.C., Muminova Z., Strong T.V., et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009, 27(50):7116-7124.
11. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003, 424(6949):681-684.
12. Asmuth D.M., Brown E.L., DiNubile M.J., Sun X., del Rio C., Harro C., et al. Comparative cell-mediated immunogenicity of DNA/DNA. DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J Infect Dis 2010, 201(1):132-141.
13. Resende D.M., Caetano B.C., Dutra M.S., Penido M.L., Abrantes C.F., Verly R.M., et al. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells. Vaccine 2008, 26(35):4585-4593.
14. Bruna-Romero O., Gonzalez-Aseguinolaza G., Hafalla J.C., Tsuji M., Nussenzweig R.S. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci U S A 2001, 98(20):11491-11496.
15. Rodriguez A., Mintardjo R., Tax D., Gillissen G., Custers J., Pau M.G., et al. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine 2009, 27(44):6226-6233.
16. Machado A.V., Cardoso J.E., Claser C., Rodrigues M.M., Gazzinelli R.T., Bruna-Romero O. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 2006, 17(9):898-908.
17. Caetano B.C., Bruna-Romero O., Fux B., Mendes E.A., Penido M.L., Gazzinelli R.T. Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of Toxoplasma gondii induces immune response and protection against infection in mice. Hum Gene Ther 2006, 17(4):415-426.
18. de Andrade B.P., Gazzinelli R.T., Del Val M., Bruna-Romero O. Protective immunization against murine cytomegalovirus infection using adenoviruses and poxviruses expressing hepatitis B virus chimeras. Int Microbiol 2007, 10(4):261-269.
19. Henderson H., Jackson F., Bean K., Panasuk B., Niezgoda M., Slate D., et al. Oral immunization of raccoons and skunks with a canine adenovirus recombinant rabies vaccine. Vaccine 2009, 27(51):7194-7197.
20. Ginsberg H.S., Horswood R.L., Chanock R.M., Prince G.A. Role of early genes in pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A 1990, 87(16):6191-6195.
21. Di Paolo N.C., Miao E.A., Iwakura Y., Murali-Krishna K., Aderem A., Flavell R.A., et al. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity 2009, 31(1):110-121.
22. Zaiss A.K., Vilaysane A., Cotter M.J., Clark S.A., Meijndert H.C., Colarusso P., et al. Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response. J Immunol 2009, 182(11):7058-7068.
23. Appledorn D.M., Patial S., McBride A., Godbehere S., Van Rooijen N., Parameswaran N., et al. Adenovirus vector-induced innate inflammatory mediators. MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 2008, 181(3):2134-2144.
24. Hartman Z.C., Kiang A., Everett R.S., Serra D., Yang X.Y., Clay T.M., et al. Adenovirus infection triggers a rapid. MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol 2007, 81(4):1796-1812.
25. Zhu J., Huang X., Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 2007, 81(7):3170-3180.
26. Muruve D.A., Petrilli V., Zaiss A.K., White L.R., Clark S.A., Ross P.J., et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008, 452(7183):103-107.
27. Weiss L.M., Dubey J.P. Toxoplasmosis: a history of clinical observations. Int J Parasitol 2009, 39(8):895-901.
28. Elmore S.A., Jones J.L., Conrad P.A., Patton S., Lindsay D.S., Dubey J.P. Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol 2010, 26(4):190-196.
29. Dubey J.P., Lindsay D.S., Speer C.A. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 1998, 11(2):267-299.
30. Khan I.A., Ely K.H., Kasper L.H. A purified parasite antigen (p30) mediates CD8+ T cell immunity against fatal Toxoplasma gondii infection in mice. J Immunol 1991, 147(10):3501-3506.
31. Angus C.W., Klivington-Evans D., Dubey J.P., Kovacs J.A. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis 2000, 181(1):317-324.
32. Bonenfant C., Dimier-Poisson I., Velge-Roussel F., Buzoni-Gatel D., Del Giudice G., Rappuoli R., et al. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect Immun 2001, 69(3):1605-1612.
33. Scorza T., D'Souza S., Laloup M., Dewit J., De Braekeleer J., Verschueren H., et al. A GRA1 DNA vaccine primes cytolytic CD8+ T cells to control acute Toxoplasma gondii infection. Infect Immun 2003, 71(1):309-316.
34. Martin V., Supanitsky A., Echeverria P.C., Litwin S., Tanos T., De Roodt A.R., et al. Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis. Clin Diagn Lab Immunol 2004, 11(4):704-710.
35. Mevelec M.N., Bout D., Desolme B., Marchand H., Magne R., Bruneel O., et al. Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice. Vaccine 2005, 23(36):4489-4499.
36. Jongert E., Verhelst D., Abady M., Petersen E., Gargano N. Protective Th1 immune responses against chronic toxoplasmosis induced by a protein-protein vaccine combination but not by its DNA-protein counterpart. Vaccine 2008, 26(41):5289-5295.
37. Liu S., Shi L., Cheng Y.B., Fan G.X., Ren H.X., Yuan Y.K. Evaluation of protective effect of multi-epitope DNA vaccine encoding six antigen segments of Toxoplasma gondii in mice. Parasitol Res 2009, 105(1):267-274.
38. McLeod R., Skamene E., Brown C.R., Eisenhauer P.B., Mack D.G. Genetic regulation of early survival and cyst number after peroral Toxoplasma gondii infection of A×B/B×A recombinant inbred and B10 congenic mice. J Immunol 1989, 143(9):3031-3034.
39. Suzuki Y., Joh K., Orellana M.A., Conley F.K., Remington J.S. A gene(s) within the H-2D region determines the development of toxoplasmic encephalitis in mice. Immunology 1991, 74(4):732-739.
40. Mack D.G., Johnson J.J., Roberts F., Roberts C.W., Estes R.G., David C., et al. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol 1999, 29(9):1351-1358.
41. Brown C.R., David C.S., Khare S.J., McLeod R. Effects of human class I transgenes on Toxoplasma gondii cyst formation. J Immunol 1994, 152(9):4537-4541.
42. Brown C.R., McLeod R. Class I MHC genes and CD8+ T cells determine cyst number in Toxoplasma gondii infection. J Immunol 1990, 145(10):3438-3441.
43. Gazzinelli R., Xu Y., Hieny S., Cheever A., Sher A. Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. J Immunol 1992, 149(1):175-180.
44. Blanchard N., Gonzalez F., Schaeffer M., Joncker N.T., Cheng T., Shastri A.J., et al. Immunodominant, protective response to the parasite Toxoplasma gondii requires antigen processing in the endoplasmic reticulum. Nat Immunol 2008, 9(8):937-944.
45. Frickel E.M., Sahoo N., Hopp J., Gubbels M.J., Craver M.P., Knoll L.J., et al. Parasite stage-specific recognition of endogenous Toxoplasma gondii-derived CD8+ T cell epitopes. J Infect Dis 2008, 198(11):1625-1633.
46. Yang Y., Xiang Z., Ertl H.C., Wilson J.M. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A 1995, 92(16):7257-7261.
47. Gazzinelli R.T., Wysocka M., Hayashi S., Denkers E.Y., Hieny S., Caspar P., et al. Parasite-induced IL-12 stimulates early IFN-γ synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol 1994, 153(6):2533-2543.
48. Hunter C.A., Subauste C.S., Van Cleave V.H., Remington J.S. Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. Infect Immun 1994, 62(7):2818-2824.
49. Denkers E.Y., Gazzinelli R.T. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 1998, 11(4):569-588.
50. Lunde M.N., Jacobs L. Antigenic differences between endozoites and cystozoites of Toxoplasma gondii. J Parasitol 1983, 69(5):806-808.
51. Sabin A.B. Toxoplasmic encephalithes in children. J Am Med Assoc 1941, 116:801-807.
52. Giraldo M., Cannizzaro H., Ferguson M.A., Almeida I.C., Gazzinelli R.T. Fractionation of membrane components from tachyzoite forms of Toxoplasma gondii: differential recognition by immunoglobulin M (IgM) and IgG present in sera from patients with acute or chronic toxoplasmosis. J Clin Microbiol 2000, 38(4):1453-1460.
53. Khan I.A., Green W.R., Kasper L.H., Green K.A., Schwartzman J.D. Immune CD8+ T cells prevent reactivation of Toxoplasma gondii infection in the immunocompromised host. Infect Immun 1999, 67(11):5869-5876.
54. Suzuki Y., Wang X., Jortner B.S., Payne L., Ni Y., Michie S.A., et al. Removal of Toxoplasma gondii cysts from the brain by perforin-mediated activity of CD8+ T cells. Am J Pathol 2010, 176(4):1607-1613.
55. Wilson D.C., Grotenbreg G.M., Liu K., Zhao Y., Frickel E.M., Gubbels M.J., et al. Differential regulation of effector- and central-memory responses to Toxoplasma gondii infection by IL-12 revealed by tracking of Tgd057-specific CD8+ T cells. PLoS Pathog 2010, 6(3):e1000815.
56. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140(6):805-820.
57. Bhadra R., Guan H., Khan I.A. Absence of both IL-7 and IL-15 severely impairs the development of CD8T cell response against Toxoplasma gondii. PLoS One 2010, 5(5):e10842.
58. Gabaglia C.R., Sercarz E.E., Diaz-De-Durana Y., Hitt M., Graham F.L., Gauldie J., et al. Life-long systemic protection in mice vaccinated with L. major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes. Vaccine 2004, 23(2):247-257.
59. Molinier-Frenkel V., Lengagne R., Gaden F., Hong S.S., Choppin J., Gahery-Segard H., et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 2002, 76(1):127-135.
60. Muruve D.A. The innate immune response to adenovirus vectors. Hum Gene Ther 2004, 15(12):1157-1166.
61. Suzuki Y., Remington J.S. Dual regulation of resistance against Toxoplasma gondii infection by Lyt-2+ and Lyt-1+. L3T4+ T cells in mice. J Immunol 1988, 140(11):3943-3946.
62. Guiton R., Zagani R., Dimier-Poisson I. Major role for CD8T cells in the protection against Toxoplasma gondii following dendritic cell vaccination. Parasite Immunol 2009, 31(10):631-640.
63. Parker S.J., Roberts C.W., Alexander J. CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice. Clin Exp Immunol 1991, 84(2):207-212.
64. Mason N.J., Liou H.C., Hunter C.A. T cell-intrinsic expression of c-Rel regulates Th1 cell responses essential for resistance to Toxoplasma gondii. J Immunol 2004, 172(6):3704-3711.
65. Sukhumavasi W., Egan C.E., Warren A.L., Taylor G.A., Fox B.A., Bzik D.J., et al. TLR adaptor MyD88 is essential for pathogen control during oral Toxoplasma gondii infection but not adaptive immunity induced by a vaccine strain of the parasite. J Immunol 2008, 181(5):3464-3473.
66. Ko H.J., Yang J.Y., Shim D.H., Yang H., Park S.M., Curtiss R., et al. Innate immunity mediated by MyD88 signal is not essential for induction of lipopolysaccharide-specific B cell responses but is indispensable for protection against Salmonella enterica serovar Typhimurium infection. J Immunol 2009, 182(4):2305-2312.
67. Park S.M., Ko H.J., Shim D.H., Yang J.Y., Park Y.H., Curtiss R., et al. MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen. J Immunol 2008, 181(9):6447-6455.
68. Krummen M., Balkow S., Shen L., Heinz S., Loquai C., Probst H.C., et al. Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. J Leukoc Biol 2010, 88(1):189-199.